Rachel Meyers serves as the chief scientific officer at Faze Medicines. She was most recently an entrepreneur-in-residence at Third Rock Ventures (TRV), where she helped drive the creation of Faze Medicines. Rachel brings more than twenty years of drug discovery and development expertise to Faze and is an expert in the development of RNAi therapeutics. Prior to joining Faze and TRV, she served as a biotech consultant in the Greater Boston area and served as SVP Research and RNAi Lead Development at Alnylam Pharmaceuticals where she spent over 13 years. Prior to Alnylam, Rachel was a senior scientist at Millennium Pharmaceuticals. She also serves on several scientific advisory boards, consults on nucleic acid therapeutic development, is listed as an inventor on many patents and patent applications, and has numerous peer-reviewed publications. She completed her postdoctoral training at Harvard Medical School in the field of signal transduction and received her PhD from MIT in the field of in vitro transcription.

Rachel also enjoys participating in women-in-science panels and events, teaching at Harvard and Brandeis, contributing in ED&I initiatives and playing a variety of sports, particularly racket sports. When Rachel isn’t engaged in one of the many things above, she is traipsing around the world with her husband and 2 kids.